All News

    Fourth Ustekinumab Biosimilar, Otulfi, Approved in US

    September 30th 2024

    By Laura Joszt

    Article

    Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.

    Future Biosimilar Trends, Challenges, and Opportunities

    September 29th 2024

    By Cameron Santoro

    Video

    Ivo Abraham, PhD, RN, University of Arizona Cancer Center, explains how biosimilars are becoming more accessible but face challenges like price erosion and potential shortages.

    Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study

    September 28th 2024

    By Deana Ferreri, PhD

    Article

    A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford University School of Medicine, gave an overview of patient-reported outcomes (PROs) in the VOLTAIRE-RA trial.

    The Top 5 Biosimilar Articles for the Week of September 23

    September 27th 2024

    By Cameron Santoro

    Video

    Here are the top 5 biosimilar articles for the week of September 23, 2024.

    Eye on Pharma: EC Approved Ustekinumab; Zymfentra Expansion; Biosimilar Policy Briefing

    September 26th 2024

    By Skylar Jeremias

    Article

    The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion expanded access to Zymfentra (subcutaneous infliximab-dyyb) through partnerships with Cigna and Express Scripts, and the Association for Accessible Medicines held a policy briefing addressing barriers to biosimilar adoption.

    IRA Reimbursement Impact on Biosimilars Minimal Despite Rising Market Share

    September 25th 2024

    By Skylar Jeremias

    Article

    The Inflation Reduction Act (IRA) has modestly boosted oncology biosimilar uptake through Medicare reimbursement, but its impact has been limited due to preexisting competitive market conditions.

    AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2

    September 24th 2024

    By Skylar Jeremias

    Article

    Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.

    BioRationality—The Missing Rationality in Biosimilar Discussions and the Path Forward

    September 23rd 2024

    By Sarfaraz K. Niazi, PhD

    Article

    The article by Sarfaraz K. Niazi, PhD, critiques the irrationality surrounding biosimilars, suggesting that regulatory changes and cost reductions in manufacturing could make biosimilars as affordable as generic drugs.

    French Study Finds High Patient Satisfaction With Adalimumab Biosimilar Treatment for IBD

    September 21st 2024

    By Deana Ferreri, PhD

    Article

    An observational study assessing patient satisfaction with adalimumab for inflammatory bowel disease (IBD) reported a high level of satisfaction with all adalimumab product, including biosimilars.

    The Top 5 Biosimilar Articles for the Week of September 16

    September 20th 2024

    By Cameron Santoro

    Video

    Here are the top 5 biosimilar articles for the week of September 16, 2024.